Arabic Arabic English English French French German German
dark

Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy

– Data include landmark median progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in patients, including those with triple-negative breast cancer (TNBC) Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs

Next Post

Ardonagh Global Partners taps new CFO

Related Posts
Total
0
Share